Literature DB >> 24894852

Expression and function of gastrin-releasing peptide (GRP) in normal and cancerous urological tissues.

Joseph Ischia1, Oneel Patel, Damien Bolton, Arthur Shulkes, Graham S Baldwin.   

Abstract

Gastrin-releasing peptide (GRP) acts as an important regulatory peptide in several normal physiological processes and as a growth factor in certain cancers. In this review we provide a comprehensive overview of the current state of knowledge of GRP in urological tissues under both normal and cancerous conditions. GRP and its receptor, GRP-R, are expressed in the normal kidney and renal cancers. GRP can stimulate the growth of renal cancer cells. GRP and GRP-R are expressed in prostate cancer and GRP can stimulate the growth of prostate cancer cell lines. Importantly, GRP is a key neuroendocrine peptide, which may be involved in the progression of advanced prostate cancer and in the neuroendocrine differentiation of prostate cancer. Recent animal studies have shown that GRP and GRP-R are an integral part of male sexual function and play a crucial role in spinal control of erections and ejaculation.
© 2014 The Authors. BJU International © 2014 BJU International.

Entities:  

Keywords:  bombesin; gastrin-releasing peptide (GRP); kidney; prostate; prostate cancer; renal cancer; sexual function

Mesh:

Substances:

Year:  2014        PMID: 24894852     DOI: 10.1111/bju.12594

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  14 in total

1.  Significance of gastrin-releasing peptide in ovarian cancer ES2 cells.

Authors:  Yanyan Jia; Huirong Shi; Dongmei Fan
Journal:  Oncol Lett       Date:  2015-05-20       Impact factor: 2.967

Review 2.  Insights into bombesin receptors and ligands: Highlighting recent advances.

Authors:  Irene Ramos-Álvarez; Paola Moreno; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Terry W Moody; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2015-05-11       Impact factor: 3.750

Review 3.  Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET.

Authors:  Phillip J Koo; Jennifer J Kwak; Sajal Pokharel; Peter L Choyke
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

Review 4.  Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors.

Authors:  Lucia Baratto; Hossein Jadvar; Andrei Iagaru
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

Review 5.  Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.

Authors:  Paola Moreno; Irene Ramos-Álvarez; Terry W Moody; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2016-03-28       Impact factor: 6.902

6.  Water-Soluble Chitosan Conjugated DOTA-Bombesin Peptide Capped Gold Nanoparticles as a Targeted Therapeutic Agent for Prostate Cancer.

Authors:  Theeranan Tangthong; Thananchai Piroonpan; Velaphi C Thipe; Menka Khoobchandani; Kavita Katti; Kattesh V Katti; Wanvimol Pasanphan
Journal:  Nanotechnol Sci Appl       Date:  2021-03-18

Review 7.  Targeted contrast agents and activatable probes for photoacoustic imaging of cancer.

Authors:  Zhenxiang Zhao; Chelsea B Swartchick; Jefferson Chan
Journal:  Chem Soc Rev       Date:  2022-02-07       Impact factor: 60.615

8.  Miniature gold nanorods for photoacoustic molecular imaging in the second near-infrared optical window.

Authors:  Yun-Sheng Chen; Yang Zhao; Soon Joon Yoon; Sanjiv Sam Gambhir; Stanislav Emelianov
Journal:  Nat Nanotechnol       Date:  2019-03-04       Impact factor: 39.213

9.  Imaging heterogeneity of peptide delivery and binding in solid tumors using SPECT imaging and MRI.

Authors:  J C Haeck; K Bol; C M A de Ridder; L Brunel; J A Fehrentz; J Martinez; W M van Weerden; M R Bernsen; M de Jong; J F Veenland
Journal:  EJNMMI Res       Date:  2016-01-14       Impact factor: 3.138

10.  Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression.

Authors:  Jingbo Qiao; Magdalena M Grabowska; Ingrid S Forestier-Roman; Janni Mirosevich; Thomas C Case; Dai H Chung; Justin M M Cates; Robert J Matusik; H Charles Manning; Renjie Jin
Journal:  Oncotarget       Date:  2016-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.